208
Participants
Start Date
January 7, 2014
Primary Completion Date
June 19, 2021
Study Completion Date
October 8, 2021
Adavosertib
Given by mouth (PO)
Carboplatin
Given intravenous (IV)
Everolimus
Given by mouth (PO)
Temozolomide
Given by mouth (PO)
Trametinib
Given by mouth (PO)
Veliparib
Given by mouth (PO)
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Emory University Hospital/Winship Cancer Institute, Atlanta
University of Kentucky/Markey Cancer Center, Lexington
Washington University School of Medicine, St Louis
M D Anderson Cancer Center, Houston
University of Colorado Hospital, Aurora
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH